Biomind Labs Inc. OTC Markets

Equities

CRSWF

CA0907021012

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:14:29 2024-04-04 pm EDT			5-day change	1st Jan Change
0.11 ^USD	-.--%		-.--%	-89.00%

2023	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
2023	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Crosswinds Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 12, 2020 at 10:31 am EDT

Crosswinds Holdings Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced net loss was CAD 72,241 compared to CAD 98,396 a year ago. Basic loss per share was CAD 0.01 compared to CAD 0.01 a year ago. For the half year, net loss was CAD 140,404 compared to CAD 156,979 a year ago. Basic loss per share was CAD 0.01 compared to CAD 0.02 a year ago.

Latest news about Biomind Labs Inc.

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	23-09-14	CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.	23-04-26	CI
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt	23-04-25	CI
Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease	22-12-28	CI
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression	22-11-14	CI
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression	22-11-04	CI
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression	22-10-11	CI
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System	22-09-27	CI
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression	22-09-21	CI
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease	22-05-26	CI
Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	22-04-26	CI
Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06	22-03-24	CI
Biomind Labs Opens a New Clinical Psychedelic Research Facility	22-03-17	CI
Biomind Labs Inc. Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression	22-03-09	CI
Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07	22-03-03	CI
Biomind Labs Inc. Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing	21-11-24	CI
Biomind Labs Inc. Completes Development of A Thermosensitive Nasal Gel Pharmaceutical Dosage Form	21-11-18	CI
Biomind Labs Files International Patent Application on its DMT Candidates Across 153 Global Jurisdictions	21-09-28	CI
Biomind Labs Inc. to Advance A Phase II Clinical Trial on DMT for Treatment-Resistant Depression	21-08-18	CI
Biomind Gets Approval in Brazil for Phase 2 DMT Depression Trial	21-08-18	DJ

Chart Biomind Labs Inc.

Duration

Period

More charts

Company Profile

Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle. Through its acceleration platform, it is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline for treating a range of therapeutic indications. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, the Company is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimerâs disease. Mescaline is a psychedelic alkaloid of the phenethylamine class. DMT Program is a serotonergic psychedelic.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research